| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Loss from operations | -5,981,008 | -4,187,357 |
| Equity-based compensation | 508,164 | 360,830 |
| Amortization of intangible assets | 423 | 282 |
| Inducement expense | - | 0 |
| Change in value of equity method investment | -338,740 | -261,820 |
| Prepaid research and development | - | 0 |
| Change in fair value contingent consideration | 150,000 | 150,000 |
| Prepaid expenses and other current assets | 99,304 | -144,592 |
| Accrued expenses | -42,934 | -137,547 |
| Accrued expenses, related party | - | 0 |
| Accounts payable | 306,154 | 420,988 |
| Accounts payable, related party | 48,272 | 48,272 |
| Net cash used in operating activities | -5,168,037 | -3,334,664 |
| Cash receipt from contingent consideration | -150,000 | -150,000 |
| Net cash provided by investing activities | 150,000 | 150,000 |
| Net proceeds from sale of common stock | 3,604,829 | 3,127,187 |
| Proceeds from warrant exercise, net of expenses | 2,268,972 | 2,221,932 |
| Net cash provided by financing activities | 5,873,801 | 5,349,119 |
| Net increase in cash and cash equivalents | 855,764 | 2,164,455 |
| Cash and cash equivalents at beginning of period | 3,750,525 | - |
| Cash and cash equivalents at end of period | 4,606,289 | - |
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)